Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours
NCT07931807, Phase 3, Not yet recruiting, The First Affiliated Hospital of University of Science and Technology of China
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours | ClinicalTrials.gov |
| NCT number | NCT07931807 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 3 | ClinicalTrials.gov |
| Enrollment | 1,395 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | The First Affiliated Hospital of University of Science and Technology of China | ClinicalTrials.gov |
| Conditions | Medium Vessel Occlusion Stroke (MeVO), Acute Ischemic Stroke | ClinicalTrials.gov |
| Interventions | Tenecteplase, Endovascular Treatment | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Functional Independence at 90 Days | 90 days after randomization (±14 days) | Proportion of participants with a modified Rankin Scale (mRS) score of 0 to 2 at 90 days, assessed by a blinded rater. The mRS ranges from 0 (no symptoms) to 6 (death). | ClinicalTrials.gov |
| Secondary | Symptomatic Intracranial Hemorrhage Within 36 Hours | Within 36 hours after randomization | Proportion of participants with symptomatic intracranial hemorrhage within 36 hours of randomization, classified as definite or probable according to the Heidelberg Bleeding Classification. This is the primary safety outcome. | ClinicalTrials.gov |
| Secondary | Shift in Modified Rankin Scale Score Distribution at 90 Days | 90 days after randomization (±14 days) | Distribution of mRS scores at 90 days. The mRS ranges from 0 (no symptoms) to 6 (death). | ClinicalTrials.gov |
| Secondary | Modified Rankin Scale Score of 0 to 1 at 90 Days | 90 days after randomization (±14 days) | Proportion of participants with an mRS score of 0 to 1 at 90 days. The mRS ranges from 0 (no symptoms) to 6 (death). | ClinicalTrials.gov |
| Secondary | Modified Rankin Scale Score of 0 to 3 at 90 Days | 90 days after randomization (±14 days) | Proportion of participants with an mRS score of 0 to 3 at 90 days. The mRS ranges from 0 (no symptoms) to 6 (death). | ClinicalTrials.gov |
| Secondary | Early Neurological Improvement at 24 Hours | 24 hours after treatment (±6 hours) | Proportion of participants with an improvement in the National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points from baseline or an NIHSS score of 0 to 1 at 24 hours. The NIHSS ranges from 0 to 42, with higher scores indicating more severe neurological deficits. | ClinicalTrials.gov |
| Secondary | NIHSS Score at 24 Hours | 24 hours after treatment (±6 hours) | The NIHSS ranges from 0 to 42, with higher scores indicating more severe neurological deficits. | ClinicalTrials.gov |
| Secondary | Change From Baseline in NIHSS Score at 24 Hours | Baseline and 24 hours after treatment (±6 hours) | Change in NIHSS score from baseline to 24 hours, calculated as the 24-hour score minus the baseline score. The NIHSS ranges from 0 to 42, with higher scores indicating more severe neurological deficits. | ClinicalTrials.gov |
| Secondary | Barthel Index at 90 Days | 90 days after randomization (±14 days) | Activities of daily living at 90 days assessed using the Barthel Index total score. Scores range from 0 to 100, with higher scores indicating greater independence. | ClinicalTrials.gov |
| Secondary | EQ-5D-5L Utility Index at 90 Days | 90 days after randomization (±14 days) | EQ-5D-5L utility index at 90 days, calculated with the Chinese value set (Luo et al., 2017). The index ranges from -0.391 to 1.000, with higher values indicating better health. | ClinicalTrials.gov |
| Secondary | Successful Reperfusion | At final angiography during the endovascular procedure | Proportion of participants with successful reperfusion, defined as an expanded Thrombolysis in Cerebral Infarction (eTICI) score ≥2b50 on final angiography. This outcome is assessed in the EVT-alone and bridging groups. | ClinicalTrials.gov |
| Secondary | First-Pass Effect | During the endovascular procedure | Proportion of participants achieving eTICI 2c to 3 reperfusion after the first thrombectomy pass without rescue treatment. This outcome is assessed in the EVT-alone and bridging groups. | ClinicalTrials.gov |
| Secondary | Successful Reperfusion at Initial Angiography | At initial angiography during the endovascular procedure | Proportion of participants randomized to bridging IVT plus EVT with successful reperfusion (eTICI ≥2b50) at initial angiography. | ClinicalTrials.gov |
| Secondary | All-Cause Mortality at 90 Days | Within 90 days after randomization | Proportion of participants who die from any cause within 90 days after randomization. | ClinicalTrials.gov |
| Secondary | Target Artery Recanalization at 24 to 72 Hours | 24 to 72 hours after randomization | Proportion of participants with patency of the target artery on computed tomography angiography (CTA) or magnetic resonance angiography (MRA), defined as a modified Arterial Occlusive Lesion (mAOL) score of 2 or 3. The mAOL scale ranges from 0 (no recanalization) to 3 (complete recanalization). This outcome is assessed in all three groups. | ClinicalTrials.gov |
| Other | Any Intracranial Hemorrhage at 24 Hours | 24 hours after treatment (±6 hours) | Proportion of participants with any new intracranial hemorrhage identified on follow-up computed tomography (CT) or magnetic resonance imaging (MRI) and classified according to the Heidelberg Bleeding Classification. | ClinicalTrials.gov |
| Other | Procedure-Related Vascular Complications | During the endovascular procedure and through the 90-day follow-up (±14 days) | Proportion of participants with at least one vascular complication related to an endovascular procedure, including vessel perforation or dissection, distal embolization or embolization into a new vascular territory, vasospasm, acute vessel occlusion, and vascular access-site hematoma, bleeding, or pseudoaneurysm. Events will be adjudicated by an independent clinical events committee. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)